Steven Reynolds, DO
Family Medicine · Long Beach, CANPI 1700893294
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,532 and has fallen 53.8% since, to $707 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$987
- AbbVie$933
- Lilly USA, LLC$522
- AstraZeneca$461
- Johnson & Johnson$400
- Antares Pharma, Inc.$294
- plus $3K from 34 others
Across 728 payments — averaging $72,806 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$14.4M
- Amgen$12.4M
- Ipsen Bioscience Inc.$4.9M
- Pfizer$4.5M
- AbbVie$4.3M
- E.r. Squibb & Sons, L.L.C.$3.3M
- plus $9.2M from 19 others
What the payments were for
- Food & beverage$6,248100%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 43 | $987 |
| AbbVie | 40 | $933 |
| Lilly USA, LLC | 24 | $522 |
| AstraZeneca | 23 | $461 |
| Johnson & Johnson | 20 | $400 |
| Antares Pharma, Inc. | 16 | $294 |
| Pfizer | 12 | $259 |
| Eisai Inc. | 10 | $218 |
| Otsuka America Pharmaceutical, Inc. | 9 | $211 |
| GSK | 9 | $197 |
| Merck | 10 | $184 |
| Boehringer Ingelheim | 6 | $127 |
| Biohaven Pharmaceuticals, Inc. | 6 | $127 |
| Amarin Pharma, Inc. | 5 | $113 |
| Boston Scientific | 4 | $107 |
| Idorsia Pharmaceuticals US Inc | 6 | $100 |
| Halozyme Inc | 4 | $97 |
| Astellas Pharma US Inc | 4 | $89 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $87 |
| Bausch Health US, LLC | 4 | $81 |
| Abbott | 2 | $58 |
| Novo Nordisk | 4 | $51 |
| Amgen | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Bayer | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Aytu Biopharma, Inc. | 1 | $37 |
| Verity Pharmaceuticals Inc. | 1 | $36 |
| Viiv Healthcare Company | 1 | $34 |
| Dexcom, Inc. | 1 | $34 |
| Tolmar, Inc. | 2 | $32 |
| Novartis | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Exact Sciences | 1 | $24 |
| SK Life Science, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Optinose US, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Neuronetics, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $16 |
How this compares
$6,268 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $46,854 |
| XareltoRivaroxaban | 14 | $23,152 |
| FarxigaDapagliflozin Propanediol | 18 | $22,053 |
| JardianceEmpagliflozin | 11 | $13,419 |
| OxycontinOxycodone Hcl | 12 | $12,063 |
| Testosterone | 38 | $5,815 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,399 |
| Propranolol Hcl ErPropranolol Hcl | 61 | $3,003 |
| Tamsulosin Hcl | 134 | $2,360 |
| Atorvastatin Calcium | 188 | $1,956 |
| Bupropion XlBupropion Hcl | 63 | $1,902 |
| Pantoprazole Sodium | 161 | $1,593 |
| Rosuvastatin Calcium | 125 | $1,591 |
| Levothyroxine Sodium | 133 | $1,523 |
| SynthroidLevothyroxine Sodium | 20 | $1,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $259 | $46,85450 claims |
| Johnson & JohnsonXarelto | $400 | $23,15214 claims |
| AstraZenecaFarxiga | $461 | $22,05318 claims |
| Boehringer IngelheimJardiance | $127 | $13,41911 claims |
| GSKAnoro Ellipta | $197 | $5,39912 claims |
| AbbVieSynthroid | $933 | $1,45120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Long Beach
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.